相关实验视频
Updated: Jul 27, 2025

10:04
Enhancing Tumor Content through Tumor Macrodissection
Published on: February 12, 2022
10.2K
关于扩散型大B细胞淋巴瘤的SEOM-GOTEL临床指南 (2022)
Josep Gumà1, Natalia Palazón-Carrión2, Antonio Rueda-Domínguez3
1Medical Oncology Department, Hospital Universitari Sant Joan de Reus, IISPV, URV, Reus, Tarragona, Spain. josep.guma@salutsantjoan.cat.
概括
扩散性大B细胞淋巴瘤 (DLBCL) 的管理依赖于R-CHOP,但像CAR T细胞这样的新疗法对复发病例显示出希望. 这些进展很快可能会挑战R-CHOP作为新诊断患者的标准.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 淋巴瘤研究 淋巴瘤研究
背景情况:
- 扩散性大B细胞淋巴瘤 (DLBCL) 是最常见的非霍奇金淋巴瘤 (NHL) 亚型.
- 两十年来,R-CHOP疗法一直是攻击性淋巴瘤的标准一线治疗方法.
- 尽管进行了广泛的研究,但对R-CHOP的修改并没有显著改善结果.
研究的目的:
- 审查DLBCL目前的护理标准.
- 讨论复发性或渐进性DLBCL治疗的不断变化的格局.
- 探索新型疗法对未来DLBCL治疗的潜在影响.
主要方法:
- 对DLBCL治疗策略的文献综述.
- 对标准和新疗法临床结果的分析.
- 讨论新兴治疗剂及其机制.
主要成果:
- R-CHOP仍然是DLBCL的第一线治疗方法.
- 没有任何R-CHOP修改可以显著改善临床结果.
- 包括CAR-T细胞和双特异性抗体在内的新型疗法正在改变复发DLBCL治疗.
结论:
- 虽然R-CHOP是新诊断的DLBCL的标准,但在复发的情况下,它的疗效有限.
- 像CAR T细胞,波拉图祖马布维多丁,塔法西他马布和双特异性抗体等新兴疗法为复发患者提供了新的希望.
- 这些新型药物准备在未来的DLBCL管理中挑战R-CHOP的基准地位.
更多相关视频
相关概念视频
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Standards of Care II
690
Nurses bear specific legal responsibilities under several federal statutes, including:
690
Secondary Lymphoid Organs
1.7K
Secondary organs, including lymph nodes, the spleen, and mucosa-associated lymphoid tissue (MALT), work harmoniously to protect us from disease and infection.
The spleen is a vital organ in the lymphatic system, nestled in the upper left side of the abdomen. It is composed of two primary regions: the red pulp and the white pulp, each having distinct functions. The red pulp performs a significant role in blood filtration. It efficiently purges the blood of old or damaged red blood cells and...
The spleen is a vital organ in the lymphatic system, nestled in the upper left side of the abdomen. It is composed of two primary regions: the red pulp and the white pulp, each having distinct functions. The red pulp performs a significant role in blood filtration. It efficiently purges the blood of old or damaged red blood cells and...
1.7K
Primary Lymphoid Organs
1.7K
Primary lymphoid organs are pivotal in the formation, development, and maturation of lymphocytes, the white blood cells that serve as the backbone of our immune system. This crucial function underscores their fundamental role in maintaining our overall health and immunity. The two primary lymphoid organs of prime importance are the red bone marrow and the thymus.
The red bone marrow is a soft, spongy tissue nestled in the interior of long bones such as the humerus and femur. It is the site...
The red bone marrow is a soft, spongy tissue nestled in the interior of long bones such as the humerus and femur. It is the site...
1.7K
Standards of Care I
731
Federal statutes profoundly impact nursing practice, providing critical guidelines to ensure patient care is equitable, accessible, and of the highest quality. The following laws address distinct aspects of healthcare provision and patient rights:
731

